Phase I/III study to confirm bioequivalence and safe switching of proposed biosimilar denosumab in postmenopausal osteoporosis

• Jean-Jacques Body,
• Christie Nie,
• Barbara Vogg,
• Richard Eastell

Affiliations

Jean-Jacques Body

Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Corresponding author.

Christie Nie

Biopharma Clinical Development, Sandoz Inc., Princeton, United States

Barbara Vogg

Department of Clinical Development, Hexal AG, a Sandoz company, Holzkirchen, Germany

Richard Eastell

Metabolic Bone Centre, Northern General Hospital, Sheffield, United Kingdom